BridgeMD
New treatment option for Urinary Calculi
Official title Tubeless Percutaneous Nephrolithotomy Without Reverse Insertion of a Ureteral Catheter
ClinicalTrials.gov ID: NCT05574517
What this study is testing
- What it's testing
- Percutaneous nephrolithotomy(PCNL) is a surgical method for upper urinary calculi. The advent of tubeless PCNL (without indwelling nephrostomy tube) has been proved to be safe and effective in reducing postoperative discomfort, shortening hospitalization time and reducing hospitalization costs.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 80
You may be able to join if
- Participants who met the the applications of PCNL surgery in the 2019 Chinese Guidelines for the Diagnosis and Treatment of Urological Diseases
- Participants who agree to undergo tubeless PCNL
- The participants' maximum diameter of the stone should be less than 3.5cm
You likely can't join if
- Confirmation by computerized tomography (CT) images and blood biochemical indicators of infectious stones or complex staghorn stones
- Obvious surgical contraindications, such as severe heart and lung insufficiency, abnormal coagulatory function
- Previous PCNL or nephrolithotomy, presence of an indwelling ureteral stent or nephrostomy tube before surgery
- Renal trauma or congenital malformation of the urinary system
The study team makes the final eligibility decision.
Where it's taking place
- Hengyang, Hunan, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 80 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Hengyang, Hunan, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.